Proton Therapy Market, By Set up Type (Single Room, and Multiple Room), By Indication (Head & Neck Cancer, Brain Cancer, Sarcoma, Pediatric Cancer, Gastro-intestinal Cancer, Prostate Cancer, and Lung Cancer), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2023

Code : CMI3672

Pages :135

Formats :

Excel and PDF

Industry : Medical Imaging

Market News

Global Proton Therapy Market: Key Developments

On April 18, 2023, Researchers from (UTSA) University of Texas at San Antonio, a public research university, and the University of Pittsburgh had collaborated to examine the use of AI (Artificial Intelligence) for adaptive radiation in the hopes that it would advance and eventually replace the present method used by physicians to evaluate images and treat tumors.

In June 2022, IBA Radiopharma Solutions , a medical technology company and provider of proton therapy solutions for the treatment of cancer, announced a contract with Eugene M. & Christine E. Lynn Cancer Institute of Boca Raton Regional Hospital, part of Baptist Health South Florida, for the installation of its ProteusONE compact proton therapy system.

In June 2022, IBA Radiopharma Solutions, a medical technology company and provider of proton therapy solutions for the treatment of cancer, announced the launch of the ConformalFLASH Alliance, which aims to accelerate the delivery of ConformalFLASH Proton Therapy to patients. ConformalFLASH is a novel delivery technique combining ultra-high dose rate FLASH radiotherapy with the unique Bragg Peak properties of protons. These ultra-high dose rates create the opportunity to optimize and accelerate the radiotherapy process and increase the therapeutic ratio.

In October 2020, Koninklijke Philips N.V., a health technology company improving people' health and well-being through meaningful innovation announced two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. The company’s artificial intelligence (AI) enabled MRCATHead and Neck radiotherapy application, which allows the use of MR as the sole or primary imaging modality for radiotherapy planning in the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis and prostate, has received U.S. FDA 510(k) clearance and is commercially available in the U.S.